Mak­er of new gene ther­a­py vec­tor launch­es its sec­ond com­pa­ny, look­ing to ze­ro in on rare skin con­di­tions

The hub-and-spoke biotech Re­play, which came on­to the scene with $55 mil­lion in seed cap­i­tal and a vi­sion to launch four com­pa­nies around its gene de­liv­ery plat­form, has al­ready launched one com­pa­ny this year, but it is not look­ing to slow down as the year starts to wrap up.

Re­play an­nounced on Mon­day that the biotech is launch­ing Telar­ia, a gene ther­a­py com­pa­ny tar­get­ing rare skin dis­eases. The top ther­a­py in Telar­ia’s pipeline is a treat­ment for re­ces­sive dy­s­troph­ic epi­der­mol­y­sis bul­losa (RDEB). This al­so marks the sec­ond of the four spin­offs that Re­play is plan­ning to launch by lever­ag­ing its “high pay­load ca­pac­i­ty” her­pes sim­plex virus (HSV) de­liv­ery vec­tor.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER